 |
 |

The Effects of a New Drug, Nylidrin, upon the Electroretinogram
JERRY HART JACOBSON, M.D.;
DEMIR BASAR, M.D.
AMA Arch Ophthalmol. 1956;56(6):865-868.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Henkes1 originally demonstrated that vasodilator drugs can increase the amplitude of the b-wave of the electroretinogram. Upon the basis of this observation we studied the effects of several vasodilator drugs, as well as the effects of stellate ganglion block, upon the ERG. These results were published a short time ago.2
Recently, we undertook an analysis of the effects, upon the ERG, of a new drug, nylidrin hydrochloride (1-[p-hydroxyphenyl]-2-[1-methyl-3-phenylprophylamino] propanol hydrochloride) (Arlidin hydrochloride).
This drug is a synthetic, belonging to the epinephrine-ephedrine group of compounds,3 and has a physiologically interesting triad of action. It increases the circulating blood volume *; it increases cardiac output,4 and it also dilates the small vessels in skeletal muscle. This latter action is thought to be due to relaxation of the smooth muscle fibers in the media of the small arteries and arterioles, and the drug is believed to act at
. . . [Full Text PDF of this Article]
Author Affiliations
New York
From the Division of Electrophysiology of the Research Department of the New York Eye and Ear Infirmary.
Footnotes
Received for publication May 24, 1956.
The Arlidin used in the study was supplied by the U. S. Vitamin Corporation. The study was supported by grants from the National Society for the Prevention of Blindness and the National Council to Combat Blindness.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|